Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPK-843 phase III open study in pulmonary mycosis
2009-014652-30Phase 3Terminated
- Sponsor
- Pro Aparts
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amcipatricin in fungal pneumonia, cryptococcal pneumonia and pulmonary aspergillosis, sponsored by Pro Aparts. Primary endpoint: Global clinical response at end of treatment and follow-up. Started Jan 2010; status: terminated.
02
Drugs
amcipatricin
03
Conditions
fungal pneumoniacryptococcal pneumoniapulmonary aspergillosis
Beyond the preview
Go deeper on 2009-014652-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014652-30.